CN101663282B - 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 - Google Patents

包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 Download PDF

Info

Publication number
CN101663282B
CN101663282B CN2008800126267A CN200880012626A CN101663282B CN 101663282 B CN101663282 B CN 101663282B CN 2008800126267 A CN2008800126267 A CN 2008800126267A CN 200880012626 A CN200880012626 A CN 200880012626A CN 101663282 B CN101663282 B CN 101663282B
Authority
CN
China
Prior art keywords
amino
trifluorophenyl
piperazine
butyryl radicals
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008800126267A
Other languages
English (en)
Chinese (zh)
Other versions
CN101663282A (zh
Inventor
金兴载
郭祐宁
申昌烈
金夏东
闵种弼
朴间珍
李在荣
崔圣贤
尹泰铉
金海鲜
张志勉
金美庆
孙文虎
金舜会
刘武嬉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong-A ST Co Ltd
Original Assignee
Dong A Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharmaceutical Co Ltd filed Critical Dong A Pharmaceutical Co Ltd
Publication of CN101663282A publication Critical patent/CN101663282A/zh
Application granted granted Critical
Publication of CN101663282B publication Critical patent/CN101663282B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008800126267A 2007-04-19 2008-04-18 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 Active CN101663282B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2007-0038462 2007-04-19
KR1020070038462 2007-04-19
KR20070038462 2007-04-19
PCT/KR2008/002203 WO2008130151A1 (en) 2007-04-19 2008-04-18 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110329468.1A Division CN102516184B (zh) 2007-04-19 2008-04-18 包含β-氨基的DPP-IV抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物

Publications (2)

Publication Number Publication Date
CN101663282A CN101663282A (zh) 2010-03-03
CN101663282B true CN101663282B (zh) 2012-02-15

Family

ID=39875638

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008800126267A Active CN101663282B (zh) 2007-04-19 2008-04-18 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物
CN201110329468.1A Active CN102516184B (zh) 2007-04-19 2008-04-18 包含β-氨基的DPP-IV抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110329468.1A Active CN102516184B (zh) 2007-04-19 2008-04-18 包含β-氨基的DPP-IV抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物

Country Status (15)

Country Link
US (1) US8030315B2 (https=)
EP (1) EP2142519B1 (https=)
JP (1) JP5148686B2 (https=)
KR (1) KR101007497B1 (https=)
CN (2) CN101663282B (https=)
AU (1) AU2008241692B2 (https=)
BR (1) BRPI0810246B1 (https=)
CA (1) CA2683696C (https=)
ES (1) ES2526338T3 (https=)
IL (1) IL201524A (https=)
MX (1) MX2009011276A (https=)
NZ (1) NZ580701A (https=)
PT (1) PT2142519E (https=)
RU (1) RU2419615C1 (https=)
WO (1) WO2008130151A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
CN102378751B (zh) * 2009-03-30 2014-08-20 东亚St株式会社 用于制备二肽基肽酶-iv抑制剂和中间体的改进方法
NZ595543A (en) * 2009-03-30 2013-05-31 Dong A Pharm Co Ltd Improved method for manufacturing dipeptidyl peptidase-iv inhibitor and intermediate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110107287A (ko) * 2010-03-24 2011-09-30 동아제약주식회사 비알콜성 지방간 질환의 예방 및 치료용 약학적 조성물
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101290029B1 (ko) 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
US20140336196A1 (en) * 2011-05-27 2014-11-13 Merck Sharp & Dohme Corp. Phosphoric acid salts of sitagliptin
CN102321014A (zh) * 2011-05-27 2012-01-18 沈阳亿灵医药科技有限公司 新型双苯基吡啶类衍生物
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
MX381222B (es) * 2013-06-26 2025-03-12 Dong A St Co Ltd Composicion para prevenir o tratar enfermedades renales, que contiene inhibidor de dpp-iv.
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
KR101709127B1 (ko) 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN107382757A (zh) * 2017-08-11 2017-11-24 苏州信恩医药科技有限公司 不对称烯丙基取代反应在依格列汀中间体合成中的应用
CN107417554A (zh) * 2017-08-15 2017-12-01 苏州信恩医药科技有限公司 一种依格列汀中间体的合成方法
KR20220165346A (ko) 2021-06-08 2022-12-15 동아에스티 주식회사 에보글립틴의 안정성이 개선된 제제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056003A1 (en) * 2003-12-09 2005-06-23 Santhera Pharmaceuticals (Schweiz) Gmbh Dpp-iv inhibitors
WO2005056541A1 (ja) * 2003-12-11 2005-06-23 Mitsubishi Pharma Corporation α-アミノ酸誘導体及びその医薬用途
WO2005095343A1 (en) * 2004-03-05 2005-10-13 Santhera Pharmaceuticals (Schweiz) Gmbh Dpp-iv inhibitors
WO2005121131A1 (en) * 2004-06-08 2005-12-22 Santhera Pharmaceuticals (Schweiz) Ag Dpp-iv inhibitors
WO2005123685A1 (en) * 2004-06-16 2005-12-29 Astrazeneca Ab Tetrahydroquinolones and aza-analogues thereof for use as dpp-iv inhibitors in the treatement of diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL204753B1 (pl) * 2000-05-25 2010-02-26 Hoffmann La Roche Podstawiony 1-aminoalkilolaktam , zawierający go środek farmaceutyczny, sposób wytwarzania podstawionego 1-aminoalkilolaktamu i jego zastosowanie
WO2001090082A1 (en) * 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
JP2002088070A (ja) * 2000-09-18 2002-03-27 Mitsubishi Rayon Co Ltd 新規ピペラジノン誘導体およびその製造方法
ATE370141T1 (de) * 2002-10-07 2007-09-15 Merck & Co Inc Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
KR20050067418A (ko) 2002-10-18 2005-07-01 머크 앤드 캄파니 인코포레이티드 당뇨병을 치료 또는 예방하기 위한 베타-아미노헤테로사이클릭 디펩티딜 펩티다제 억제제
AU2004261186A1 (en) 2003-07-31 2005-02-10 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20090124601A1 (en) 2005-03-29 2009-05-14 Song Zhiguo J Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor
JP2008031064A (ja) * 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056003A1 (en) * 2003-12-09 2005-06-23 Santhera Pharmaceuticals (Schweiz) Gmbh Dpp-iv inhibitors
WO2005056541A1 (ja) * 2003-12-11 2005-06-23 Mitsubishi Pharma Corporation α-アミノ酸誘導体及びその医薬用途
WO2005095343A1 (en) * 2004-03-05 2005-10-13 Santhera Pharmaceuticals (Schweiz) Gmbh Dpp-iv inhibitors
WO2005121131A1 (en) * 2004-06-08 2005-12-22 Santhera Pharmaceuticals (Schweiz) Ag Dpp-iv inhibitors
WO2005123685A1 (en) * 2004-06-16 2005-12-29 Astrazeneca Ab Tetrahydroquinolones and aza-analogues thereof for use as dpp-iv inhibitors in the treatement of diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mohane Selvaraj Coumar et al.3-[2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.《Bioorganic & Medicinal Chemistry Letters》.2006,第17卷1274-1279. *

Also Published As

Publication number Publication date
CA2683696C (en) 2012-05-22
AU2008241692A1 (en) 2008-10-30
HK1172613A1 (en) 2013-04-26
EP2142519A4 (en) 2011-07-13
EP2142519A1 (en) 2010-01-13
WO2008130151A1 (en) 2008-10-30
US20100120790A1 (en) 2010-05-13
KR20080094604A (ko) 2008-10-23
EP2142519B1 (en) 2014-09-24
RU2419615C1 (ru) 2011-05-27
JP5148686B2 (ja) 2013-02-20
BRPI0810246A2 (pt) 2015-08-18
BRPI0810246B1 (pt) 2021-11-30
MX2009011276A (es) 2010-01-15
CN102516184B (zh) 2015-03-25
CN101663282A (zh) 2010-03-03
AU2008241692B2 (en) 2011-02-10
HK1138272A1 (en) 2010-08-20
IL201524A (en) 2014-09-30
KR101007497B1 (ko) 2011-01-12
US8030315B2 (en) 2011-10-04
PT2142519E (pt) 2014-12-11
CA2683696A1 (en) 2008-10-30
NZ580701A (en) 2011-07-29
JP2011500508A (ja) 2011-01-06
CN102516184A (zh) 2012-06-27
ES2526338T3 (es) 2015-01-09
IL201524A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
CN101663282B (zh) 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物
US10398677B2 (en) N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN101233147B (zh) 丙型肝炎病毒的大环抑制剂
JP2008031064A (ja) ジアシルピペラジン誘導体
EP2890683A1 (en) Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN101754957A (zh) 新的杂环基化合物和它们作为趋化因子拮抗剂的用途
TW200938530A (en) Pyrrolidine compounds
WO2006098342A1 (en) Piperazinyl compounds
CN104024232A (zh) 新吡嗪衍生物
NZ289498A (en) Piperidinylpiperazine derivatives such as various piperidinylpiperazinylacetylphenoxy acetic acid derivatives, pharmaceutical compositions
US20240374738A1 (en) Bifunctional compound capable of degrading receptor tyrosine kinase and application thereof
CN102112451A (zh) 用作趋化因子受体调节剂的二氮杂环庚烷和哌嗪衍生物
CN110352191A (zh) 吡咯烷酮化合物
CN102256605B (zh) 包含抑制二肽基肽酶-iv活性的化合物以及其他抗糖尿病剂或抗肥胖剂作为活性成分的、用于预防和治疗糖尿病或肥胖症的药物组合物
CN102153538B (zh) 苯并环衍生物
HK1172613B (en) Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
HK1138272B (en) Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
ES2481790T3 (es) Profármacos de [4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(1H-pirrolo-piridin-il)-metanonas y síntesis de los mismos
CN109134367B (zh) 一种抑制rock的化合物及其用途
CN108164506A (zh) 一种dpp-4酶抑制剂及其制备和应用
CN105814027A (zh) 用于终末分化细胞和组织再生的新化合物
HK40067957A (en) Thienopyrimidine derivatives as lpa receptor 2 inhibitors
JPWO2000063171A1 (ja) 三環性化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1138272

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1138272

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: DONG-A ST CO., LTD.

Free format text: FORMER OWNER: EAST ASIA PHARMACEUTICAL CO., LTD.

Effective date: 20140723

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140723

Address after: Seoul, South Korea

Patentee after: DONG-A ST CO., LTD.

Address before: Seoul, South Korea

Patentee before: East-Asia Pharmaceutical Co., Ltd.